F-Prime Capital β 2021 Investments
6 investments dated 2021 Β· listed companies and verified rows first Β· show all
Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform.
BiotechMedical DevicesBerkeley, US
Jennifer Doudna(Co-founder)Rachel Haurwitz(President and Chief Executive Officer, Co-founder)Martin Jinek(Co-founder)Andrew May(Executive Officer)
BoardJenny Rooke(Director)
Board seatRobert WeisskoffΒ· per SEC Form D
Co-investorsAliment CapitalAvego BioScience CapitalIA Seed VenturesMission Bay CapitalMission BiocapitalPontifax AgTech+2 more
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
Rene Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Paul Clancy(Director)Daniel Curran(Director)Nancy Hong(Director)
Board seatRobert WeisskoffΒ· per SEC Form D
Co-investorsBain Capital Life SciencesBay City CapitalM VenturesMRL Ventures FundRA CapitalRiverVest Venture Partners+4 more
Boston, US
Board seatCarl ByersΒ· per SEC Form D Β· $75M raise Β· filed Jul 2021
Co-investorsFounder CollectiveMaterial
Snapdocs automates the digital mortgage closing process by connecting lending, settlement, and secondary market teams.
AI & Machine LearningFintechLegalTechPropTechSaaSPortland, US
Aaron King(Founder/CEO)inMatt Schindel(Executive Officer)Sanam Pangali(Executive Officer)
BoardAndrew Reed(Director)inAnu Hariharan(Director)
Board seatDavid JegenΒ· per SEC Form D
Co-investors137 VenturesAccelerator VenturesAlkeon InnovationMetaPropMetaProp VenturesRed Swan Ventures+9 more
Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.
BiotechCambridge, US
Andrew Ashe(Executive Officer)Sekar Kathiresan(Executive Officer, Director)Andrew Bellinger(Executive Officer)
BoardJohn Evans(Director)Anthony Philippakis(Director)inKrishna Yeshwant(Director)in
Co-investorsARCH Venture PartnersGV (Google Ventures)RA CapitalvenBio PartnersForesite Capital
WellBeam offers an EMR-integrated solution that connects acute and post-acute care providers, letting physicians and advanced practice providers authorize home health orders, respond to clinician concerns, and manage patient status after discharge.
Digital HealthHealthtechSaaSPalo Alto, US
Amee Devani(CEO & Co-Founder)Pascal Odek(CTO & Co-Founder)James Huie(Executive Officer)
Co-investorsOncology VenturesUlu Ventures
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.